Oppenheimer Reaffirms “Buy” Rating for LHC Group (LHCG)

Oppenheimer restated their buy rating on shares of LHC Group (NASDAQ:LHCG) in a report released on Thursday. Oppenheimer currently has a $85.00 price target on the health services provider’s stock.

Other research analysts also recently issued reports about the stock. Royal Bank Of Canada restated a buy rating and issued a $70.00 price target on shares of LHC Group in a research report on Wednesday, September 6th. Jefferies Group raised their price target on shares of LHC Group from $68.00 to $83.00 and gave the stock a buy rating in a research report on Tuesday, November 7th. They noted that the move was a valuation call. Zacks Investment Research downgraded shares of LHC Group from a buy rating to a hold rating in a research report on Friday, November 10th. Robert W. Baird set a $71.00 price target on shares of LHC Group and gave the stock a hold rating in a research report on Tuesday, November 28th. Finally, SunTrust Banks restated a buy rating and issued a $75.00 price target on shares of LHC Group in a research report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $77.10.

Shares of LHC Group (NASDAQ LHCG) traded down $1.82 during mid-day trading on Thursday, reaching $62.09. 319,120 shares of the company’s stock traded hands, compared to its average volume of 274,386. The firm has a market cap of $1,134.94, a price-to-earnings ratio of 26.65, a P/E/G ratio of 1.84 and a beta of 0.69. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.77 and a current ratio of 1.77. LHC Group has a 52 week low of $41.66 and a 52 week high of $76.14.

LHC Group (NASDAQ:LHCG) last announced its quarterly earnings data on Monday, November 6th. The health services provider reported $0.64 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.60 by $0.04. The company had revenue of $272.90 million during the quarter, compared to analyst estimates of $265.35 million. LHC Group had a net margin of 4.09% and a return on equity of 9.52%. The firm’s revenue for the quarter was up 18.2% compared to the same quarter last year. During the same period last year, the business earned $0.54 EPS. equities research analysts predict that LHC Group will post 2.4 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of LHCG. Federated Investors Inc. PA lifted its position in LHC Group by 4.2% in the 2nd quarter. Federated Investors Inc. PA now owns 1,622 shares of the health services provider’s stock valued at $110,000 after purchasing an additional 66 shares during the last quarter. Acrospire Investment Management LLC lifted its position in LHC Group by 30.8% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,700 shares of the health services provider’s stock valued at $115,000 after purchasing an additional 400 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in LHC Group by 758.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 1,716 shares of the health services provider’s stock valued at $116,000 after buying an additional 1,516 shares during the period. First Mercantile Trust Co. acquired a new position in LHC Group during the 2nd quarter valued at about $147,000. Finally, SG Americas Securities LLC acquired a new position in LHC Group during the 3rd quarter valued at about $163,000. Hedge funds and other institutional investors own 85.51% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Oppenheimer Reaffirms “Buy” Rating for LHC Group (LHCG)” was published by Week Herald and is the property of of Week Herald. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://weekherald.com/2017/12/10/oppenheimer-reaffirms-buy-rating-for-lhc-group-lhcg.html.

About LHC Group

LHC Group, Inc is a holding company. The Company provides post-acute healthcare services to patients through its home nursing agencies, hospice agencies, community-based services agencies and long-term acute care hospitals (LTACHs). The Company operates through four segments: home health services, hospice services, community-based services and facility-based services.

Analyst Recommendations for LHC Group (NASDAQ:LHCG)

Receive News & Ratings for LHC Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply